[The treatment of psoriatic arthropathy with a combination of mefenamic and aminocaproic acids].
Studies of the connective tissue status, lysosomal enzymes and kallikrein-kinin system activities in 30 patients with psoriatic arthropathy have revealed an increased level of the connective tissue matrix and collagen metabolites, elevated activities of proteoglycan-destroying hydrolases and of kallikrein and its precursor. The detected shifts correlated with the severity of the skin and articular processes. Besides the traditional local and fortifying therapy, the patients have been administered mefenamic acid (connective tissue stabilizer) and aminocaproate (tissue protease and kinin system inhibitor). Such treatment has been effective in 76% of the patients. The mean length of treatment has made up 42.3 days. The drugs have had a positive effect on both the skin and articular processes. A tendency to normalization of the biochemical characteristics has been observed. The suggested scheme of therapy is recommended for practice.
N A
NA
Kuliev
D000293:Adolescent; D000328:Adult; D000614:Aminocaproates / Q000627:therapeutic use*; D015119:Aminocaproic Acid / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy* / Q000378:metabolism; D002908:Chronic Disease; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008528:Mefenamic Acid / Q000627:therapeutic use*; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism
D000614:Aminocaproates; D008528:Mefenamic Acid; D015119:Aminocaproic Acid
Lechenie psoriaticheskoĭ artropatii sochetaniem mefenamovoĭ i aminokapronovoĭ kislot.